Evidence map›Paper›PMID 40637984›Full record

Trial reportInternational journal of language & communication disorders

The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria.

Avril Nicoll, Marian C Brady, Patricia Masterson-Algar, Christopher Burton, Gillian Beaton, Sylvia Dickson, Maria Caulfield, Christina H Smith, Carl E Clarke, Natalie Ives and 5 more

Abstract readClinical Trial, Phase IIIMulticenter StudyPragmatic Clinical Trial
In one paragraph

Trial report in International journal of language & communication disorders. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Avril NicollAberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.ORCID https://orcid.org/0000-0001-9677-4817
Marian C BradySchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.ORCID https://orcid.org/0000-0002-4589-7021
Patricia Masterson-AlgarSchool of Health Sciences, Bangor University, Bangor, UK.ORCID https://orcid.org/0000-0001-6344-1346
Christopher BurtonSchool of Health Sciences, University of East Anglia, Norwich, UK.ORCID https://orcid.org/0000-0003-1159-1494
Gillian BeatonNHS Greater Glasgow and Clyde, SLT Department, New Victoria Hospital, Glasgow, UK.ORCID https://orcid.org/0000-0002-8539-9318
Sylvia DicksonSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.ORCID https://orcid.org/0000-0002-4137-5752
Maria CaulfieldCentre for Applied Dementia Studies, Faculty of Health Studies, University of Bradford, Bradford, West Yorkshire, UK.ORCID https://orcid.org/0009-0006-8933-8076
Christina H SmithNHS Lothian, Speech & Language Therapy Department, Department of Clinical Neurosciences, Edinburgh, UK.ORCID https://orcid.org/0000-0001-7803-9616
Carl E ClarkeDepartment of Applied Health Sciences, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0003-2478-3436
Natalie IvesBirmingham Clinical Trials Unit, College of Medicine and Health, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0002-1664-7541
Sue JowettBirmingham Clinical Trials Unit, College of Medicine and Health, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0001-8936-3745
Caroline RickNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-7713-9834
Rebecca WoolleyBirmingham Clinical Trials Unit, College of Medicine and Health, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0001-5119-1431
Catherine M SackleySchool of Health Science, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0002-8580-6622
on behalf of the PD COMM collaborative group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs people with Parkinson's experience progressive communication changes, effective, implementable speech and language therapy (SLT) interventions are needed. Process evaluations alongside pragmatic randomised controlled trials (RCTs) are of clinical value if they describe, compare and understand the implementation of trial interventions. This paper reports the PD COMM process evaluation. PD COMM was a large, UK multi-centre phase III pragmatic RCT of SLT in the National Health Service (NHS). It recruited 388 people with Parkinson's who were randomised to Lee Silverman Voice Treatment (LSVT), Standard NHS SLT, or no dysarthria intervention.

aimsTo describe and compare the content and service delivery components of the PD COMM SLT interventions; understand experiences of implementing LSVT; explain trial outcomes; and reflect on implications for practice and research. METHODS AND PROCEDURES: We took a pragmatic, mixed methods approach. The intervention description team used a sub-sample of routine therapy notes and trial record forms, the Template for Intervention Description and Replication (TIDieR) and simple descriptive statistics to compare Individual Participant Therapy Data (LSVT n = 51; Standard NHS SLT n = 54). In parallel, informed by Normalisation Process Theory (NPT), the implementation team conducted qualitative interviews with a sub-sample of therapists (n = 20) and participants (n = 24) to understand the additional work of implementing LSVT. The core process evaluation team met to integrate the findings in relation to the trial outcomes. OUTCOMES AND

resultsLSVT was largely delivered per protocol, tailored to participants' interests and interactions. Dosage was a key difference between the two interventions, commonly achieved by two or more therapists delivering LSVT. Effective mechanisms were LSVT's structured design, repetitive and social nature, practise requirements and focus on volume. Standard NHS SLT was eclectic, reflecting a range of clinical approaches at a lower intensity, including some techniques and activities in common with LSVT. Although focused on impairment therapy, including specific voice therapy techniques, it also featured cognitive-linguistic and psychosocial targets and low technology augmentative and alternative communication (AAC). The trial design may have limited opportunities for group intervention. CONCLUSIONS AND IMPLICATIONS: Any LSVT roll-out needs service support and coordination, and should take an inclusive approach. Future research of Standard NHS SLT should explore a rationale for dosage and more explicit tailoring to individuals and their families. There is also a pressing need to deliver the benefits of LSVT in a cost-effective manner and to develop a range of evidence-based, implementable alternatives as people's communication support needs change. WHAT THIS PAPER ADDS: What is already known on the subject Lee Silverman Voice Treatment (LSVT) has a body of incrementally-developed evidence from effectiveness trials but has not previously been tested in a pragmatic randomised controlled trial (RCT) with an embedded process evaluation. What this paper adds to the existing knowledge This mixed methods process evaluation paper describes and compares content and service delivery components to understand similarities and differences between LSVT and Standard NHS SLT interventions and experiences of implementing LSVT in the UK NHS. What are the potential or actual clinical implications of this work? Services can use the findings to plan delivery of intensive interventions and to reflect on the content and service delivery aspects of locally Standard NHS SLT and how it might be improved.

Indexed as

DysarthriaLanguage TherapyParkinson DiseaseSpeech TherapyVoice TrainingAgedFemaleHumansMaleMiddle AgedProcess Assessment, Health CareTreatment OutcomeUnited Kingdomimplementation scienceintervention studyParkinson diseasepragmatic clinical trialrandomized controlled trialspeech and language therapy

Identifiers

PMID40637984
PMCPMC12244302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.